Clovis Bags Rociletinib After FDA Rejection

Source: OneLive

May 13, 2016

Clovis Oncology has announced that it will stop clinical development of rociletinib, its once-promising EGFR inhibitor for the treatment of patients with non–small cell lung cancer.

The FDA has notified the Colorado-based drugmaker of an upcoming complete response letter -- meaning the agency will not approve Clovis' NDA based on available data.

Clovis also reported that it is under federal investigation surrounding erroneous rociletinib- data that was posted in the New England Journal of Medicine last year.

Read the OneLive article

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments